Skip to search formSkip to main contentSkip to account menu

CKD 516

Known as: CKD-516, CKD516, Tubulin Polymerization Inhibitor CKD-516 
A benzophenone derivative and water soluble valine prodrug of the tubulin binding agent S516, with potential tubulin-inhibiting, vascular-disrupting… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
We report a phase I pharmacological study of an oral formulation of CKD‐516, a vascular‐disrupting agent, in patients with… 
2020
2020
Purpose CKD-516 (Valecobulin), a vascular-disrupting agent, inhibits microtubule elongation. We evaluated the effect of CKD-516… 
2014
2014
AIM To evaluate the anticancer efficacy of CKD-516, a novel vascular-disrupting agent, alone and in combination with doxorubicin… 
2014
2014
SummaryPurpose CKD-516 is a benzophenone analog in which the B ring is modified by replacement with a carbonyl group. The study… 
2013
2013
Purpose: To evaluate the usefulness of dynamic contrast-enhanced ultrasonography (DCE-US) in the early quantification of… 
2013
2013
ZusammenfassungHintergrundÜber einen Zeitraum von 10 Jahren hat sich die Prävalenz älterer Menschen an der Dialyse verdoppelt… 
2012
2012
Przewlekla choroba nerek (CKD) jest bardzo rozpowszechnionym schorzeniem wspolistniejącym z wieloma chorobami ukladu sercowo… 
2010
2010
Latar belakang Mortalitas pasien penyakit ginjal kronik yang menjalani hemodialisa tinggi, 60 % karena komplikasi kardiovaskuler…